BioPhy Raises $4.5M in Funding


BioPhy, a Philadelphia, PA-based company providing an AI operating system to advance promising drug candidates, raised $4.5M in funding.

The round was led by Chelsea Clinton and Caroline Kassie’s Metodora Ventures, Audere Capital, and TRCM, as well as Jeff Marrazzo, the Co-Founder of Spark Therapeutics.

The company intends to use the funds to expand its R&D sector, operations and its business reach.

Led by CEO Dave Latshaw II, BioPhy is working to transforming the way promising drugs are identified, developed, and tested. With its patent-pending predictive AI engine, BioPhy is focused on enhanceing the outcomes of clinical trials, reducing failure rates and accelerating the pace of developing new drugs with the goal of improving the quality of healthcare outcomes across the globe.

BioPhy works with pharmaceutical and life science companies, including innovators like Ambrose Healthcare, to identify promising target/drug opportunities and design their clinical trials. Its AI operating system for drug development currently consists of two products:

  • BioPhyRx: a generative AI solution designed to create a centralized, intuitive environment for accessing scientific and regulatory resources. Using large language models, this platform helps pharmaceutical companies in all stages of development by analyzing and interpreting scientific literature, clinical trials, regulatory guidelines and submissions, quality assurance documents, and other industry-specific sources to provide accurate and up-to-date information on demand.
  • BioLogicAI: a predictive AI engine that provides customized insights to aid life science companies through all stages of the drug development process including clinical trial endpoint predictability, indication selection, licensing, drug repurposing, asset acquisitions, and divestment. BioLogicAI also benchmarks the biological feasibility of preclinical assets against those in development or already approved by the FDA.